Just throwing this out there, maybe totally off the market, but is there any chance that the review of nonclinical data might be for fast track status? Or does that classification happen later in the trial process (if at all)?
Delay = Buy Opportunity, page-21
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $73.55M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 22.0¢ | 20.5¢ | $264.9K | 1.250M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 47501 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.0¢ | 4460 | 1 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |